<DOC>
	<DOCNO>NCT01472614</DOCNO>
	<brief_summary>This open clinical study 12 week therapy investigate clinical efficacy safety add-on therapy DLBS3233 improve blood glucose control , lipid profile , adiponectin subject type-2 diabetes mellitus .</brief_summary>
	<brief_title>Efficacy Safety Add-on Therapy With DLBS3233 Patients With Type-2 Diabetes Mellitus</brief_title>
	<detailed_description>There one group study receive study treatment follow : anti-diabetic agent currently use respective subject least 3 month prior Screening , treatment intensification ( lifestyle modification ) , DLBS3233 dose 100 mg daily 12 week . Clinical laboratory examination evaluate investigational drug 's efficacy safety perform baseline interval 6 week 12-week course therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male subject age 40 70 year ; female subject age 55 70 year ( postmenopause ) screening Diagnosed type2 diabetes mellitus Have treat combination two OHA least 3 month prior screen A1c level &gt; = 7.0 % Hemoglobin level &gt; = 10 g/dL Body Mass Index ( BMI ) &gt; 18.5 kg/m2 Refuse insulin therapy Able take oral medicine Subjects symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Uncontrolled hypertension define systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg History current chronic treatment insulin History renal and/or liver disease Impaired liver function : serum ALT &gt; 2.5 time upper limit normal positive result chronic acute hepatitis B C test Impaired renal function : serum creatinine &gt; = 1.5 time upper limit normal Current treatment systemic corticosteroid herbal ( alternative ) medicine Any disease state uncontrolled illness , judge investigator , could interfere trial participation trial evaluation Participation clinical study within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Type-2 diabetes mellitus</keyword>
	<keyword>Add-on therapy</keyword>
</DOC>